Zhu, C., Zhou, Z., Roos, I., Merlo, D., Kalincik, T., Ozakbas, , Skibina, O., Kuhle, J., Hodgkinson, S., Boz, C., Alroughani, R., Lechner-Scott, J., Barnett, M., Izquierdo, G., Prat, A., Horakova, D., Kubala Havrdova, E., Macdonell, R., Patti, F., Khoury, S. J., Slee, M., Karabudak, R., Onofrj, M., Van Pesch, V., Prevost, J., Monif, M., Jokubaitis, V., van der Walt, A., & Butzkueven, H. (2022). comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis. Journal of neurology, neurosurgery and psychiatry, 93(12), 1330–1337. http://access.bl.uk/ark:/81055/vdc_100169537975.0x00005f